Proxy Votes Now

Home › Funds › Jackson National › JNL/Mellon Healthcare Sector Fund

JNL/Mellon Healthcare Sector Fund proxy voting record 2025-2026

Fund family: Jackson National · Filed by JNL SERIES TRUST (CIK 933691) · SEC series S000068125

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,282 with, 35 against, 32 abstentions (not counted as with management). Shareholder proposals: 7 FOR, 28 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Jackson National as a whole

The same two figures as Jackson National’s manager page (239,981 ballot items across 107 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsJackson NationalItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)93.4%1,26492.4%203,335
Backed environmental and social shareholder proposals at US companiesn/a92.8%2,611

Where this fund voted differently from most Jackson National funds

Each ballot item this fund voted is set against the votes of the other Jackson National funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Jackson National funds on 17 items (1.4% of the 1,252 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Jackson National fundsMgmtResult
CENCORA, INC.2026-03-05Advisory vote to approve the fiscal 2025 compensation of Cencora, Inc.'s named executive officers.AgainstFOR — 11 of 17 Jackson National fundsAgainstApproved, 93.2% support
INTUITIVE SURGICAL, INC.2026-04-30To approve, by advisory vote, the compensation of the Company's Named Executive Officers.AgainstFOR — 8 of 14 Jackson National fundsAgainstApproved, 94.0% support
RADNET, INC.2026-06-02An advisory vote to approve the compensation of the Company's Named Executive Officers.AgainstFOR — 4 of 6 Jackson National fundsAgainstApproved, 94.0% support
RADNET, INC.2026-06-02DIRECTOR: Laura P. JacobsAbstainFOR — 4 of 6 Jackson National fundsAgainst—
DOXIMITY, INC2025-08-28To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers for the fiscal year ended March 31, 2025.AgainstFOR — 4 of 6 Jackson National fundsAgainstPassed (calculated), 96.4% support
NUVALENT, INC.2026-06-16Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.WithholdFOR — 4 of 6 Jackson National fundsAgainstElected, 81.5% support
DANAHER CORPORATION2026-05-05To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. A. Shane SandersAgainstFOR — 7 of 13 Jackson National fundsAgainst—
DANAHER CORPORATION2026-05-05To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Raymond C. Stevens, Ph.DAgainstFOR — 7 of 13 Jackson National fundsAgainst—
DANAHER CORPORATION2026-05-05To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified. Teri L. ListAgainstFOR — 7 of 13 Jackson National fundsAgainst—
MOLINA HEALTHCARE, INC.2026-05-06To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers.ForAGAINST — 4 of 7 Jackson National fundsForPassed (calculated), 52.8% support
REPLIGEN CORPORATION2026-05-14Election of Directors Karen A. DawesAgainstFOR — 4 of 7 Jackson National fundsAgainst—
MODERNA, INC.2026-05-06To approve, on a non-binding, advisory basis, the compensation of our named executive officers.ForAGAINST — 3 of 5 Jackson National fundsForApproved, 65.1% support
GUARDANT HEALTH, INC.2026-06-17Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.AgainstFOR — 3 of 5 Jackson National fundsAgainstNot approved, 90.8% support
RHYTHM PHARMACEUTICALS, INC.2026-06-24DIRECTOR: David W.J. McGirrAbstainFOR — 2 of 3 Jackson National fundsAgainst—
IRHYTHM HOLDINGS, INC.2026-05-27To approve the adoption of our 2026 Equity Incentive Plan.AgainstFOR — 2 of 3 Jackson National fundsAgainstApproved, 98.0% support
VIKING THERAPEUTICS INC2026-05-19DIRECTOR: J. Matthew SingletonForABSTAIN — 2 of 3 Jackson National fundsFor—
VIKING THERAPEUTICS INC2026-05-19TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.ForAGAINST — 2 of 3 Jackson National fundsForApproved, 70.2% support

Download all 17 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 99.3% of this fund’s 1,349 such votes could be given a sector; the other 9 (0.7%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care1,185322.7%
Industrials10222.0%
Consumer Staples2015.0%
Technology1900.0%
Consumer Discretionary1400.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections9210
Say-on-Pay1430
Audit-related1330
Corporate Governance5722
Compensation492
Capital Structure300
Other111
Human Rights or Human Capital/workforce66
Shareholder Rights and Defenses61
Other Social Issues33

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
ELI LILLY AND COMPANYMay 4, 2026$497M102
JOHNSON & JOHNSONApril 23, 2026$295M151
ABBVIE INC.May 8, 2026$225M81
UNITEDHEALTH GROUP INCORPORATEDJune 1, 2026$160M121
MERCK & CO., INC.May 26, 2026$154M183
THERMO FISHER SCIENTIFIC INC.May 20, 2026$111M130
AMGEN INC.May 19, 2026$107M151
GILEAD SCIENCES, INC.April 30, 2026$90M153

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026ELI LILLY AND COMPANYShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026ELI LILLY AND COMPANYShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026JOHNSON & JOHNSONIndependent Board Chair Shareholder proposalAgainstFor
May 8, 2026ABBVIE INC.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
June 1, 2026UNITEDHEALTH GROUP INCORPORATEDIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 19, 2026AMGEN INC.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 23, 2026PFIZER INC.Adopt an Independent Chair Policy Shareholder proposalAgainstFor
May 13, 2026VERTEX PHARMACEUTICALS INCORPORATEDShareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

1,360 ballot items at 137 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, JNL/Mellon Healthcare Sector Fund voted at 137 shareholder meetings of 133 companies, on 1,360 ballot items in all. Where management made a recommendation, the fund followed it on 95.0% of the items and voted against it 35 times. Its most frequent area of disagreement was corporate governance (22 of its votes against management). It voted on 35 shareholder proposals. It voted FOR the board's own proposals more often than Jackson National's funds as a whole (93.4% against 92.4%). It voted differently from most Jackson National funds on 17 items. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Jackson National’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.